Hahn said the changes the agency will keep include a greater focus on decentralized clinical trials, ramping up laboratory-developed tests and increasing the use of telemedicine technology.
The FDA said it also is pivoting toward the use of real-world evidence to monitor medical products amid the pandemic.
More articles on pharmacy:
American Pharmacists Association swears in new CEO
5 recent CMS pharmacy policy changes
Eli Lilly testing COVID-19 drug derived from survivor blood
